EU/3/04/192: Orphan designation for the treatment of myelodysplastic syndromes

"3-(4'Aminoisoindoline-1'-one)-1-piperidine-2,6-dione (lenalidomide)

Overview

This medicine is now known as lenalidomide.

Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in December 2019 upon request of the marketing authorisation holder.

On 8 March 2004, orphan designation (EU/3/04/192) was granted by the European Commission to Gregory Fryer Associates Limited, United Kingdom, for 3-(4'aminoisoindoline-1'-one)-1-piperidine-2,6-dione for the treatment of myelodysplastic syndromes.

The sponsorship was transferred to Celgene Europe Limited in July 2005.

3-(4'aminoisoindoline-1'-one)-1-piperidine-2,6-dione in treatment of myelodysplastic syndromes has been authorised in the EU as Revlimid since 13 June 2013.

The sponsorship was transferred to Celgene Europe B.V., The Netherlands, in July 2018.

Key facts

Active substance
"3-(4'Aminoisoindoline-1'-one)-1-piperidine-2,6-dione (lenalidomide)
Intended use
Treatment of myelodysplastic syndromes
Orphan designation status
Withdrawn
EU designation number
EU/3/04/192
Date of designation
08/03/2004
Sponsor
Celgene Europe B.V.
Winthontlaan 6 N
3526 KV Utrecht
Telephone: +31 (0)30 284 4547
E-mail: medinfo.intl@celgene.com

Review of designation

Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in December 2019 upon request of the marketing authorisation holder.

During its meeting of 14-15 May 2013, the Committee for Orphan Medicinal Products (COMP) reviewed the designation EMA/OD/083/03 for Revlimid (lenalidomide, previously known as 3-(4'aminoisoindoline-1'-one)-1-piperidine-2,6-dione) as an orphan medicinal product for the treatment of myelodysplastic syndromes. The COMP assessed whether, at the time of addition of a new indication to the marketing authorisation, the medicinal product still met the criteria for orphan designation. The Committee looked at the seriousness and prevalence of the conditions, and the existence of other satisfactory methods of treatment. As other methods of treatment for patients with myelodysplastic syndromes are authorised in the European Union (EU), the COMP also looked at the significant benefit of the product over existing treatments. The COMP recommended that the orphan designation of the medicine be maintained1.


1 The maintenance of the orphan designation at time of marketing authorisation would, except in specific situations, give an orphan medicinal product 10 years of market exclusivity in the EU. This means that in the 10 years after its authorisation similar products with a comparable therapeutic indication cannot be placed on the market.

Documents related to this orphan designation evaluation

  • List item

    Recommendation for maintenance of orphan designation at the time of addition of a new indication to the marketing authorisation: Revlimid (lenalidomide) for the treatment of myelodysplastic syndromes (PDF/127.13 KB)

    Adopted

    First published: 19/07/2013
    Last updated: 19/07/2013
    EMA/COMP/288804/2013

  • Patients' organisations

    For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

    • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

    • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

    EU register of orphan medicines

    The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

    How useful was this page?

    Add your rating
    Average
    1 rating